Gumarontinib
As of the edition of 20 October 2026, Gumarontinib is a small molecule: marketed, first approved in 2024 (JP); acts on MET.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2024
- Kind
- Small molecule
- Brand name
- Haiyitan
- First approved
- 24 June 2024 (JP)
- Approvals on record
- 2 in 1 region
- Holder of the most recent approval
- Haihe Biopharma
- Registered trials
- 11, 0 stopped early
- Disease areas
- Cancer; Lungs and airways; Digestive system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Gumarontinib.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| MET | Hepatocyte growth factor receptor | P08581 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 3 | 3 | 0 | 0 |
| Phase 2 | 6 | 0 | 5 | 0 |
| Phase 3 | 2 | 0 | 2 | 0 |
| All trials | 11 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Haihe Biopharma | Applicant and Lead sponsor of trials | 2017 to now |